Two temperature-sensitive (ts) mutants (ts 21 and ts 24), which could complement each other, were isolated from cell culture-passaged murine cytomegalovirus (CC-MCMV). Characterization in vivo revealed that ts 21 lacked pathogenicity for suckling mice, neurovirulence for weanling mice and productive chronic infection in the salivary gland, whereas ts 24 was positive only for the first two parameters; both mutants retained immunogenicity comparable to that of the wild-type CC-MCMV. The immunogenicity of ts 21 and ts 24 was assessed by mortality of the immunized mice after challenge with virulent, salivary gland-passaged MCMV (SG-MCMV) and by replication of the challenge virus in the immunized hosts. The protective immunity conferred by ts 21 was maintained over a period of 3 months without production of infectious viruses in the salivary gland.
INTRODUCTION
Cytomegalovirus (CMV) infects the host by vertical as well as by horizontal transmission. The most important aspect of CMV is congenital infection of the newborn, who may suffer from neurological sequelae. Another important aspect of CMV is infection of patients undergoing renal transplantation (for review, see Osborn, 1981) . In an attempt to prevent infection by exogenous CMV, two groups of virologists initiated vaccination with live, cell culture-passaged CMV (Elek & Stern, 1974; Plotkin et al., 1976) . However, since human CMV is highly speciesspecific, these vaccines have no experimental animal model in which pathogenicity and the mechanism of immunity can be studied. For this reason, we have employed murine cytomegalovirus (MCMV) as a model for human cytomegalovirus (HCMV), because the pattern of MCMV infection in mice simulates that of HCMV infection (for review, see Hudson, 1979) and mice are easy to manipulate.
It has been reported that MCMV is attenuated by passage in vitro (Osborn & Walker, 1970) and that the attenuated MCMV is immunogenic for mice (Osborn & Walker, 1970; Howard & Balfour, 1977; Minamishima & Eizuru, 1974; Minamishima et al., 1978a) . Consequently, the cell culture-passaged MCMV (CC-MCMV) is effective as a live vaccine against challenge by virulent, salivary gland-passaged MCMV (SG-MCMV). However, it has some limitations as a vaccine. First, attenuated MCMV is still pathogenic for suckling mice (Eizuru & Minamishima, 1979) . Second, it can grow in the brains of weanling mice (Ohsaki et al., 1970; Lussier, 1973; Minamishima et al., 1978 b) . Third, attenuated MCMV establishes chronic, productive infection in the salivary gland. Fourth, once replicated in the salivary gland, the virus reverts to the virulent state (Osborn & Walker, 1970) and may be shed. Therefore, we have attempted to obtain viruses lacking these properties.
Since any temperature-sensitive (ts) mutant is usually less virulent than its parent virus, we expected ts mutant(s) of MCMV to meet that requirement and a candidate virus has been isolated. This paper is concerned with the pathogenicity and immunogenicity of ts mutants of CC-MCMV. ~Truses. The Smith strain of MCMV, supplied by Professor T. Nakao, Sapporo Medical College, was passaged in mice more than 10 times via the intraperitoneal route and the supernatant fluid ofa 10}0 (w/v) homogenate of the salivary gland was used as the virulent MCMV (SG-MCMV). MCMV passaged in MEF more than 20 times was used as the attenuated MCMV (CC-MCMV). The CC-MCMV was plaque-purified three times in MEF at 39 'JC and designated wild-type virus. Cell-free virus, released from infected MEF by three cycles of freeze thawing and freed of cell debris by low-speed centrifugation, was stored at -70 °C until used.
Titration o/'ciruses. Stock viruses were assayed by the plaque method under a 2 ~o methyl cellulose overlay in a 5 °/o CO_, atmosphere at 34 °C (permissive temperature), or at 39 ~C (non-permissive temperature), as required. Infectious viruses in mouse organs were similarly titrated by using the supernatant fluid of a 10% (w/v) homogenate in Eagle's MEM and virus titres are presented as means _+ standard deviation.
Mutugenesis of CC-MCMV with u.r. light. Virus stocks of wild-type CC-MCMV (0.6 hal) were placed in 35 mm tissue culture dishes (Falcon) and exposed to u.v. light by means of a germicidal lamp (15 W, two tubes) at a distance of 40 cm for 180 s with constant agitation. This treatment reduced the infectivity from approximately l06 to 103 p.f.u. After exposure, monolayers of MEF were inoculated with the irradiated virus and the cells were incubated at 34 °C until maximum cytopathic effect (c.p.e.) appeared. The cultures were then harvested as described above and used as u.v.-mutagenized virus stocks. These mutagenized virus stocks, diluted fivefold in Hanks' balanced salt solution, were disrupted by ultrasonication for 5 s and passed through 450 nm membrane filters (Sartorius). MEF seeded on a Microtest II plate (Falcon) were infected with these suspensions so that each well received 0.5 p.f.u, of virus, and incubated at 34 °C. The contents of the wells that showed c.p.e, were collected individually and inoculated onto MEF grown in duplicate microplates. One plate was incubated at 34 °C and the other at 39 °C. Viruses which showed little or no c.p.e, at 39 °C but advanced c.p.e, at 34 °C were selected as candidates for ts mutants and further plaque-purified at 34 °C.
Thermal inactivation. Virus stocks diluted 100-fold in Eagle's MEM (final serum concentration of 0.05~0) were disrupted by ultrasonication for 5 s and passed through 450 nm membrane filters to remove virus aggregates. Samples of these virus suspensions were incubated at 39 °C for 10, 20 and 30 min, cooled in ice and assayed immediately for residual infectivity.
Complementation test. Monolayers of MEF were infected with pairs of mutants at a multiplicity of infection of 0-2 of each mutant (i.e. a combined multiplicity of 0.4 p.f.u./cell). In parallel, MEF were infected with each mutant separately at a multiplicity of infection of 0-4. The infected cells were incubated at 39 °C for 48 h and assayed for virus by incubation at 34 °C after three cycles of freeze-thawing. The complementation index (CI) was defined as the yield of mixed infection divided by the sum of the yields of the two single infections. Complementation was considered positive when the Cl was higher than 2.
Mice. Female 4-to 5-week-old ICR mice were used as weanling mice and 1-to 2-day-old mice as suckling mice. Nude mice having a BALB/c background were obtained from Shizuoka Agricultural Cooperative Association for Laboratory Animals (Hamamatsu, Shizuoka, Japan).
Neutrali:ation test. Before the test, sera from immunized mice were inactivated at 56 '~C for 30 rain. Serial fourfold dilutions of serum (0.2 ml) were reacted with CC-MCMV or SG-MCMV (600 p.f.u, in 0.2 ml of Eagle's M EM supplemented with 5 o calf serum) and guinea-pig complement (0-2 ml) for 30 rain at 37 ~C and the mixture was assayed for residual infective virus by inoculating 0" 1 ml onto MEF monolayers. Neutralizing antibody titres were expressed as the highest serum dilution showing 50°o plaque reduction.
RESULTS

In vitro characteristics of ts mutants
Two ts mutants (ts 21 and ts 24) were isolated from 117 plaques of mutagenized wild-type virus of CC-MCM¥. Efficiency of plating (e.o.p.) and efficiency of replication (e.o.r.) of the ts mutants are shown in Table 1 . The possibility that temperature-sensitivity was associated with increased thermal lability of the virions was excluded by testing thermal inactivation of these viruses (data not shown), indicating that the temperature-sensitivity is associated with the replication cycle.
Complementation tests between ts 21 and ts 24 revealed that they belonged to different complementation groups; virus yields from ts 21 alone, ts 24 alone and mixed infection of ts 21 and ts 24 were 2 x 10, 4 × 10 and 3,3 x l0 s p.f.u./ml, respectively, and the complementation index of this pair was 5.5 x 103. * Two-day-old ICR mice were inoculated intraperitoneally with 2-0 x 103 p.f.u, of CC-MCMV per 0.1 nal. Six days later, the organs were removed from the mice and viruses were titrated at 34 °C. Three mice (experiment i) and five mice (experiment 2) were used.
Pathogenicity of ts mutants for suckling mice
First, the mortality of suckling mice infected with wild-type and ts mutants was compared.
When 2.0 x 104 p.f.u, of virus was inoculated intraperitoneally, the mortality was 4/5, 0/5 and 2/3 for wild-type, ts 21 and ts 24, respectively. Second, replication of these viruses in suckling mice was compared. When 2.0 × 103 p.f.u., a sub-lethal dose, was inoculated intraperitoneally into 2-day-old mice, little virus was detected in the organs on the 6th day after inoculation of ts 21, corresponding to the mortality (Table 2) . Third, the pathogenicity for suckling mice was determined by oral inoculation. When suckling mice (within 24 h, three mice per group) were inoculated orally with 3.0 x 103 p.f.u, of virus, infectious virus was recovered from the brain, kidney and salivary gland of the mice infected with wild-type but not with ts 21 or ts 24 (data not shown). Thus, ts 21 had lost pathogenicity for suckling mice.
Replication of ts mutants in weanling mice
Usually, CC-MCMV did not replicate in organs of ICR mice other than salivary gland and pancreas after intraperitoneal inoculation, but did replicate in the brain after intracerebral inoculation, in weanling mice (Ohsaki et al., 1970; Lussier, 1973 ; Minamishima et al., 1978 b) . Therefore, wild-type virus and ts mutants were examined for replication in vivo.
First, when 1.0 x 10 s p.f.u, of the viruses was inoculated intraperitoneally into weanling mice (two and five mice per virus strain in expts. 1 and 2, respectively), none of the ts mutants was recovered from the mouse organs on day 11 (those examined were brain, salivary gland, thymus, lung, heart, liver, kidney, adrenal gland, spleen, pancreas and lymph node). In contrast, under the same conditions, wild-type virus replicated in the salivary gland and pancreas. The mean virus titres (p.f.u./organ) were 1900 _+ 820 and 51000 _ 75 000 (expts. 1, 2) for the former, and 500 + 120 and 1900 _+ 1300 (expts. 1, 2) for the latter.
Second, the salivary glands of mice inoculated intraperitoneally with wild-type virus and ts 21 were monitored for infectious viruses on 4, 7, 10, 21, 28 and 42 days after inoculation. While the salivary glands of wild-type virus-infected mice were invariably positive for infectious virus after 10 days (ranging from 6-4 x 102 to 2.2 x 10~), mice inoculated with ts 21 remained negative (less than 100 p.f.u./organ).
Third, after intracerebral inoculation of 1.0 x 104 p.f.u, of virus, ts 21 showed no replication in the brain, whereas ts 24 replicated although to a lesser degree than wild-type virus : on day 4, mean virus titres in the brains (seven to ten mice per group) were 12000 + 18000, < 100 and 100 _+ 83 for wild-type, ts 21 and ts 24, respectively. In a separate experiment, the brains of mice inoculated intracerebrally with wild-type and ts 21 viruses were monitored for infectious virus every 2 days up to 8 days. In the case of wild-type, infectious virus reached a peak on day 4 and then declined to undetectable levels by day 8. In contrast, ts 21 remained undetectable (data not shown).
Immunogenicity of ts mutants
Immunogenicity of ts mutants was assessed by the mortality of immunized mice after challenge with virulent SG-MCMV and by replication of the challenge virus in the immunized hosts.
First, intraperitoneal inoculation of 1.0 x 105 p.f.u, of each ts mutant protected mice against intraperitoneal challenge on day 7 with 2.0 x 106 p.f.u. (approximately 3 LDso) of virulent SG-MCMV. To determine the minimum effective doses, mice were inoculated intraperitoneally with tenfold serial dilutions of wild-type virus or with each ts mutant and then similarly challenged. As shown in Table 3 , 1.0 x 102 p.f.u, of both mutants as well as wild-type virus protected mice repeatedly from fatal infection by SG-MCMV. However, some of the mice immunized with ts mutants at this dose recovered after showing clinical signs such as ruffled fur, lethargy and photophobia. With lower doses, however, the results were variable.
Second, the efficacy of immunization with ts mutants was confirmed by its inhibitory effect on replication of the challenge virus in vivo. In this particular system, any virus recovered from the challenged mice was the challenge virus itself, since ts mutants used for immunization were unable to replicate in the mice. Several organs of mice immunized 7 days before challenge were titrated for infectious virus. Although there was some fluctuation, ts mutants as well as wild-type virus generally inhibited in vivo replication of the challenge virus as clearly shown in Table 4 . In particular, ts 21 completely suppressed infection of the challenge virus, suggesting that this would be the most desirable candidate for a model vaccine.
Third, attempts were made to determine whether the protective immunity endowed by ts mutants can be maintained without production of infectious virus in the salivary glands. Mice 9'3(+ 13) x 10 z 7.0(_+11) x 10 a <102 <102 Thymus 1 5.9(_+4-2) × 103 < 10-" < 10 z < 102 2 3.2(_+20) x 103 < 102 < 102 < 102 Lung 1 1.5(_+ 1.1) x 10 a < 102 < 102 < 102 2 4.2(_+2.3) x 10 a < 102 < 102 < 102 Heart 1 3"4(+0.3) x 10 4 < 10 2 < 102 < 10 2 2 5'7(_+4.4) x 10 3 < 10 2 < 10 2 < 10 2 Lwer 1 2.8(_+ 1.6) x 10 a < 10 2 < 10 2 < 10 2 2 1"5(_+1"3)× 10 ~ <102 <102 <102 Kidney 1 6.8(_+3.9) x 10 a < 102 < 102 < 102 2 3.5( _+ 2-7) x 10 ~ < 102 < 102 < 102 Adrenal gland 1 4.1(_+0.1) × 103 < 102 < 102 < 102 2 2.6( + 3-3) x 104 < 10-" < 102 < 102 Spleen 1 6-3(-+3.4) x l0 s 1.3(+ 1.3) x 102 < 102 < 102 2 1"6(+0"8) x 106 <102 <102 6"6(-+_ 13) x 1O z Pancreas 1 3-2(-+ 1.9) x 104 1-8(_+1.8) × 103 <102 <102 2 7.7(-+5"8) × 103 2"1(-+2"2) × 103 < 102 < 102 Lymph node 1 1.5(_+ 1-4) x 103 < 102 < 102 < 102 2 1-8(-+ 1"8) x 10 2 < 10 2 < 10 2 < 10 2 * Four-week-old female ICR mice were immunized intraperitoneally with 1.0 x 105 p.f.u, of CC-MCMV per 0.5 ml and 7 days later challenged intraperitoneally with 1.4 x 106 p.f.u, of SG-MCMV per 0.5 ml. Organs were removed from mice 4 days after challenge and infectious virus was titrated at 34 ~C. • Four-week-old female ICR mice were inoculated intraperitoneally with 1.0 x 105 p.f.u, of CC-MCMV per 0-5 ml. A group of mice were sacrificed for infectious virus assay and for antibody titration, and other groups were challenged by SG-MCMV.
Mean values of p.f.u./organ of three mice (experiment 1) and five mice (experiment 2). ++ Mean values of complement-requiring neutralizing antibody titre in the mouse sera.
Number of surviving mice/number of mice challenged by 2.0 × 106 p.f.u, of SG-MCMV.
immunized with wild-type, ts 21 and ts 24 were examined at 1 and 3 months for infectious virus in the salivary gland, serum-neutralizing antibody against both CC-MCMV and SG-MCMV, and survival after challenge by SG-MCMV (Table 5 ). The salivary glands of mice inoculated with both ts mutants were negative for infectious virus over a period of 3 months, yet the immunized mice resisted challenge by virulent SG-MCMV. In those mice, neutralizing antibody was undetectable in the absence of guinea-pig complement. When tested in the presence of complement, however, neutralizing antibody against CC-MCMV, but not against SG-MCMV used for challenge, was detected, as shown in Table 5 . Thus, complement-requiring neutralizing antibody was induced by ts mutants even without obvious replication. However, the neutralizing antibody did not cross-react with the challenge virus, suggesting that it is not a prerequisite for protective immunity. Fourth, the efficacy of immunization was compared in euthymic and athymic mice under similar conditions. Nude mice (nu/nu) and their litter mates (nu/+) were either not immunized or were immunized with 1.0 x 105 p.f.u, of wild-type, ts 21 or ts 24 virus (three mice/group), and then challenged with 2.0 x 106 p.f.u, of SG-MCMV. While all nu/+ mice except the nonimmunized controls survived challenge, none of the nu/nu mice including the immunized ones resisted challenge (data not shown). Thus, the immunization was nullified in the athymic nude mice, indicating that the immunity is thymus-dependent, supporting previous reports (Minamishima, 1977; Starr & Allison, 1977; Ho & Ashman, 1979) .
The in vivo characteristics of the ts mutants are summarized in Table 6 .
DISCUSSION
Several ts mutants of HCMV have been isolated and characterized (Yamanishi & Rapp, 1977; Ihara et al., 1978) . However, since there is no experimental animal for HCMV, studies have been limited to analysis in vitro. In contrast, ts mutants of MCMV, described here, make possible experiments in vivo to elucidate pathogenicity and immunogenicity.
In isolating ts mutants of MCMV, much attention has been paid to the fact that MCMV contains a multicapsid virion (Hudson et al., 1976a) . The ts mutants were isolated by repeating three cycles of sonication, filtration and plaque purification. A 450 nm filter is expected to allow the passage of enveloped virions containing one or two capsids but not those containing more capsids. If an enveloped particle contained two nucleocapsids, the virus would be picked up as a ts mutant only when the nucleocapsids were both temperature-sensitive. In other cases, the virion would replicate and produce plaques at non-permissive temperature. However, we cannot exclude the possibility that a ts mutant plaque may contain different ts mutants belonging to the same complementation group, although the probability of this should have been minimized by repeated plaque-purification.
Attenuation of ts 21 was apparently associated with its inability to replicate in vitro at the nonpermissive temperature. In the case of ts 24, however, there was some discrepancy between these parameters. Thus, it is unknown whether or not attenuation in the ts mutants simply reflects the temperature-sensitivity observed in vitro. It is of relevance that ts + revertants of attenuated ts mutants of various viruses do not always regain virulence (Belshe et al., 1978 ; MacKenzie, 1975; Trousdale et al., 1979) . The possibility that an unselected mutation other than temperaturesensitivity may be involved in the attenuation cannot be ruled out.
Both ts mutants retained immunogenicity and prior inoculation with 100 p.f.u, of ts mutants or with the wild-type virus protected mice from fatal infection by virulent SG-MCMV. However, the following points regarding the effective dose of the virus should be mentioned. First, MCMV shows 20-to 80-fold higher infectivity by centrifugal inoculation (Osborn & Walker, 1968; Hudson et al., 1976b) . Therefore, 100 p.f.u, of ts mutants, as assayed by the normal method, may actually contain more infectious virus particles that are countable by centrifugal assay. Second, most of the MCMV particles that propagate in cell cultures are multicapsid virions (Hudson et at., 1976a) . This indicates that many nucleocapsids in an enveloped particle (1 p.f.u.) were actually inoculated into the mice. Third, it is also conceivable that the virus stock contains defective and/or inactivated viruses. It is relevant here to mention that formalin-killed MCMV, if given in sufficient quantity, is able to elicit immunity in mice, although the efficacy is lower than that of live, attenuated MCMV (Tolpin et al., 1980) . When live viruses are inoculated into mice, two kinds of immunogen are available: one is the structural components of the virion and the other is virus-induced surface antigens on the infected cells. The ts mutants, especially ts 21, cannot produce progeny viruses in weanling mice, yet a small dose can elicit potent immunity in the mice. Therefore, it is likely that the protective antigen is mainly surface antigen(s) of the infected cells and that antigen(s) is induced even at the nonpermissive temperature, although not identified so far.
It should be noted that the immunity can be maintained without productive, chronic infection of MCMV in the salivary glands. Although the infectious virus was undetectable by a conventional method, it is possible that the virus genome persists latently and is partially expressed to synthesize the antigen. It has been documented that MCMV causes latent infection after chronic, productive infection, and that it can be reactivated by various manipulations (Olding et al., 1975 ; Mayo et al., 1977; Cheung & Lang, 1977 ; Jordan et al., 1977 ; Jordan, 1980) . Latency and subsequent reactivation remain to be examined.
It is also of interest that under such conditions, neutralizing antibody against the challenge virus (SG-MCMV) was not detected even in the presence of complement, although complement-requiring neutralizing antibody was detectable against the homologous virus (CC-MCMV) ( Table 5 ). Lack of cross-neutralization between these viruses was also shown by Chong et al. (1981) . One of the available explanations is that SG-MCMV is masked by non-neutralizing antibody (mouse IgG) (Chong et al., 1981) . In separate experiments using mouse antiserum and goat anti-mouse IgG serum, we confirmed their results, the only difference being that addition of complement alone did not significantly reduce the infectivity of SG-MCMV (Y. Minamishima et al., unpublished data) .
Several live vaccines for herpesvirus infections have been licensed in the U.S.A. for use in veterinary medicine (Parks & Rapp, 1975) . For humans, a live varicella virus vaccine has been developed for high-risk patients in Japan (Takahashi et al., 1975) . However, the vaccine virus can persist in the treated patient and may be reactivated to produce herpes zoster. Concerning HCMV, some candidate vaccines have been proposed for clinical application, although there are arguments for and against their use (Lang, 1980; Osborn, 1981; Plotkin, 1981) . More information is required on the criteria for attenuation and on the fate of the vaccine virus, such as latency, reactivation, reversion and shedding. Although no attempt has been made so far to apply ts mutants of HCMV to humans, a measles virus vaccine, designated AIK-C, is temperature-sensitive and has achieved its purpose with few side effects (Makino, 1977) .
As an experimental model, MCMV will complement HCMV in the study of pathogenicity and immunogenicity. An apathogenic and immunogenic ts mutant of MCMV, ts 21, can be used as model vaccine, and it may offer a means of solving problems in the pathogenesis and immunoprophylaxis of CMV infection.
